A Review of Localized Prostate Cancer: An African Perspective.

Active surveillance Localized prostate cancer Prostate specific antigen Radical prostatectomy

Journal

World journal of oncology
ISSN: 1920-454X
Titre abrégé: World J Oncol
Pays: Canada
ID NLM: 101564097

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 16 07 2019
accepted: 30 07 2019
entrez: 23 10 2019
pubmed: 23 10 2019
medline: 23 10 2019
Statut: ppublish

Résumé

Prostate cancer is the second most common malignancy in males and the sixth leading cause of cancer mortality in men with a relatively higher death rate in men of African descent. In the United States and other parts of Europe, more than 80% of diagnosed prostate cancer is localized, and 80-90% of these men receive some form of treatment. The projected data may not be a direct reflection of the disease in the sub-Saharan region as less than 40% presents with localized disease. Results from prostate cancer screening have shown that most African men in the sub-region have little knowledge of the disease. There are recommended international guidelines for the management of localized prostate cancer, however, a guideline in a local context could be ideal.

Identifiants

pubmed: 31636789
doi: 10.14740/wjon1221
pmc: PMC6785274
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

162-168

Informations de copyright

Copyright 2019, Cassell et al.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest regarding this article.

Références

Afr J Urol. 2013 Dec;19(4):165-170
pubmed: 25221428
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Infect Agent Cancer. 2011 Sep 23;6 Suppl 2:S6
pubmed: 21992406
Prostate Cancer. 2012;2012:691380
pubmed: 23251806
ISRN Urol. 2013 Apr 24;2013:832496
pubmed: 23710370
Niger J Clin Pract. 2011 Jul-Sep;14(3):363-7
pubmed: 22037086
Pan Afr Med J. 2013 Aug 10;15:129
pubmed: 24255735
Urology. 2010 Aug;76(2):412-6
pubmed: 20451979
J Urol. 1997 Apr;157(4):1340-3
pubmed: 9120935
Prostate Cancer. 2013;2013:560857
pubmed: 23476788
Prog Urol. 2009 Feb;19(2):112-5
pubmed: 19168014
Can J Urol. 2008 Feb;15(1):3886-9
pubmed: 18304399
J Natl Med Assoc. 2006 Apr;98(4):539-43
pubmed: 16623066
Prog Urol. 2014 Apr;24(5):271-5
pubmed: 24674331
BMC Cancer. 2013 Jan 16;13:23
pubmed: 23324165
Health Expect. 2015 Dec;18(6):2079-90
pubmed: 24506829
East Afr Med J. 2007 Sep;84(9 Suppl):S31-5
pubmed: 18154200
Niger Postgrad Med J. 2011 Jun;18(2):98-104
pubmed: 21670775
Prog Urol. 2013 Jan;23(1):36-41
pubmed: 23287482
ISRN Oncol. 2011;2011:943704
pubmed: 22091437

Auteurs

Ayun Cassell (A)

Department of Urology and Andrology, Hopital General de Grand Yoff, Dakar, Senegal.

Bashir Yunusa (B)

Department of Surgery, Liberia College of Physicians and Surgeons, Monrovia, Liberia.

Mohamed Jalloh (M)

Department of Urology and Andrology, Hopital General de Grand Yoff, Dakar, Senegal.

Mouhamadou M Mbodji (MM)

Department of Urology and Andrology, Hopital General de Grand Yoff, Dakar, Senegal.

Abdourahmane Diallo (A)

Department of Urology and Andrology, Hopital General de Grand Yoff, Dakar, Senegal.

Madina Ndoye (M)

Department of Urology and Andrology, Hopital General de Grand Yoff, Dakar, Senegal.

Saint Charles Kouka (SC)

UFR Sante, Universite de Thies, Thies, Senegal.

Issa Labou (I)

Department of Urology and Andrology, Hopital General de Grand Yoff, Dakar, Senegal.

Lamine Niang (L)

Department of Urology and Andrology, Hopital General de Grand Yoff, Dakar, Senegal.

Serigne M Gueye (SM)

Department of Urology and Andrology, Hopital General de Grand Yoff, Dakar, Senegal.

Classifications MeSH